Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir, Daclatasvir and Ribavirin for HCV Cirrhosis
NCT02596880Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2015
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of sofosbuvir, daclatasvir, ribavirin in hepatitis C (HCV), sponsored by Tehran University of Medical Sciences. Started Sep 2015; status: completed.
02
Drugs
sofosbuvirdaclatasvirribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02596880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02596880.